China Pharma Holdings, Inc.CPHINYSE
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank79
3Y CAGR-42.6%
5Y CAGR+29.6%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-42.6%/yr
Quarterly compound
5Y CAGR
+29.6%/yr
Recent deceleration
Percentile
P79
Within normal range
vs 5Y Ago
3.7x
Strong expansion
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 92.44% |
| Q2 2025 | -29.19% |
| Q1 2025 | 5308.96% |
| Q4 2024 | -99.38% |
| Q3 2024 | -46.69% |
| Q2 2024 | 422.51% |
| Q1 2024 | -78.68% |
| Q4 2023 | 222.36% |
| Q3 2023 | 92.75% |
| Q2 2023 | 3.21% |
| Q1 2023 | -17.83% |
| Q4 2022 | -68.45% |
| Q3 2022 | 489.17% |
| Q2 2022 | -72.13% |
| Q1 2022 | 0.00% |
| Q4 2021 | 152.87% |
| Q3 2021 | -60.02% |
| Q2 2021 | -71.88% |
| Q1 2021 | -27.30% |
| Q4 2020 | 594.89% |
| Q3 2020 | 25.24% |
| Q2 2020 | -38.46% |
| Q1 2020 | -9.59% |
| Q4 2019 | 35.95% |
| Q3 2019 | -39.83% |
| Q2 2019 | -5.59% |
| Q1 2019 | 8.51% |
| Q4 2018 | 3.83% |
| Q3 2018 | 162.14% |
| Q2 2018 | 6.58% |
| Q1 2018 | 44.04% |
| Q4 2017 | -44.01% |
| Q3 2017 | 28.41% |
| Q2 2017 | -17.69% |
| Q1 2017 | -66.06% |
| Q4 2016 | -22.52% |
| Q3 2016 | 2.52% |
| Q2 2016 | 3.45% |
| Q1 2016 | -57.68% |
| Q4 2015 | -45.55% |